Polydex Pharmaceuticals (OTCMKTS:POLXF) Vs. LIN, APD, JSCPY, TROX, MTX, KRO, LXU, VHI, LXFR, and NL
Should you be buying Polydex Pharmaceuticals stock or one of its competitors? The main competitors of Polydex Pharmaceuticals include Linde (LIN), Air Products and Chemicals (APD), JSR (JSCPY), Tronox (TROX), Minerals Technologies (MTX), Kronos Worldwide (KRO), LSB Industries (LXU), Valhi (VHI), Luxfer (LXFR), and NL Industries (NL). These companies are all part of the "industrial inorganic chemicals" industry.These companies are all part of the "industrial inorganic chemicals" industry.
Polydex Pharmaceuticals vs.
Linde (NYSE:LIN) and Polydex Pharmaceuticals (OTCMKTS:POLXF) are both oils/energy companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
Linde has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Polydex Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.
Linde currently has a consensus price target of $370.67, suggesting a potential upside of 15.79%. Given Linde's higher probable upside, equities research analysts plainly believe Linde is more favorable than Polydex Pharmaceuticals.
Linde has higher revenue and earnings than Polydex Pharmaceuticals. Polydex Pharmaceuticals is trading at a lower price-to-earnings ratio than Linde, indicating that it is currently the more affordable of the two stocks.
Linde received 242 more outperform votes than Polydex Pharmaceuticals when rated by MarketBeat users. However, 69.11% of users gave Polydex Pharmaceuticals an outperform vote while only 68.70% of users gave Linde an outperform vote.
Linde has a net margin of 12.66% compared to Polydex Pharmaceuticals' net margin of -4.99%. Linde's return on equity of 12.62% beat Polydex Pharmaceuticals' return on equity.
73.0% of Linde shares are held by institutional investors. 0.7% of Linde shares are held by insiders. Comparatively, 12.9% of Polydex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Linde had 6 more articles in the media than Polydex Pharmaceuticals. MarketBeat recorded 6 mentions for Linde and 0 mentions for Polydex Pharmaceuticals. Linde's average media sentiment score of 0.10 beat Polydex Pharmaceuticals' score of 0.00 indicating that Linde is being referred to more favorably in the media.
Summary
Linde beats Polydex Pharmaceuticals on 15 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding POLXF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Polydex Pharmaceuticals (OTCMKTS:POLXF) vs. Its Competitors
Polydex Pharmaceuticals Competitors List
